curriculum vitae€¦ · al-tahan am, al-jumah ma, bohlega sm, al-shammari sn, al-sharoqi ia, hosny...
Post on 24-Aug-2020
0 Views
Preview:
TRANSCRIPT
1
CURRICULUM VITAE
A. PERSONAL EXPERIENCE:
1. PERSONAL INFORMATION
Name: Bassem I. Yamout
D.O.B: April 19th, 1961
Nationality: Lebanese
Department: Internal medicine, School of medicine, American University of
Beirut Medical Center, Beirut-Lebanon.
2. EDUCATIONAL BACKGROUND
1977-1980: BS-American University of Beirut, Beirut-Lebanon.
1979-1984: MD-American University of Beirut, Beirut-Lebanon
1983-1984: Internship _ American University of Beirut.
1984-1987: Neurology Residency _ University of Cincinnati Medical Center.
1987-1988: Neuromuscular fellowship Montreal Neurological Institute, McGill
University, Montreal-Canada.
3. ACADEMIC APPOINTMENTS
1988-1990: Assistant Professor of internal medicine at the American University
of Beirut.
1990-1998: Clinical Assistant Professor of Internal Medicine at the American
University of Beirut.
1998-2011: Clinical Associate Professor of Internal Medicine at
the American University of Beirut.
2011-Present: Clinical Professor of Neurology at the American University of
Beirut
2011-Present: Director, Multiple Sclerosis Center Clinical Research.
American University of Beirut Medical Center
4. BOARD CERTIFICATION
2
Certified by the American board of neurology and psychiatry: 1990
5. AWARDS/ HONORS
1- Elected Fellow of the American Academy of Neurology, 2011
2- Jeanne-Timins Fellowship Award, Montreal Neurological Institute, 1987.
3- Dean’s honor list A.U.B. 1978 and 1979.
B. PUBLICATIONS:
1. ARTICLES
1. Yamout B, Zeineddine M, Sawaya R and Khoury S. Safety and Efficacy of
Reduced Fingolimod Dosage Treatment. J Neuroim 2015 (In Press)
2. Yamout B, Alroughani R, Al-Jumaa M, Goueider R, Dahdaleh M, Inshasi J,
Hashem S, Alsharoqi I,Sahraian, M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al
Khaburi J, Alsaadi T, Bohlega S. Consensus Recommendations for the Diagnosis
and Treatment of Multiple Sclerosis:The Middle East North Africa Committee for
Treatment and Research in Multiple Sclerosis (MENACTRIMS). Current Medical
Research and Opinion 2015 (In Press)
3. Rahhal E, Hajjar H, Rajeh M, Abdelnoor AM and Yamout B. EBV and HHV-6A
DNA enhance IL-17 production in BALB/c mice and in HHV-6 infected cells from
multiple sclerosis patients. Viral Immunology 2015 (In Press)
4. Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H. Risk factors for
Multiple Sclerosis and associations with anti-EBV antibody titers. Clinical
Immunology 2015 (In Press)
5. Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi I, AlTahan A,S
Bohlega, Daif A, Deleu D, Amous A, Inshasi J, Rieckmann P, Sahraian M,
Yamout B. Functional clinical outcomes in multiple sclerosis: Current status and
future prospects. Multiple Sclerosis and Related Disorders 2015; 4:192-201
6. Rizk M, El Khatib M, Yamout B, Hujeily E, Ayoub S, Ayoub C, Skaf G.
Spontaneous intracranial hypotension syndrome treated with fludrocortisone.
Anesthesia and Analgesia Case Reports 2015; 4:8-11
7. Alroughani R, Aref H, Bohlega S, Dahdaleh M, Feki I, Al Jumah M, Al Kawi M,
Koussa S, Sahraian M, Alsharoqi I, Yamout B. Natalizumab treatment for multiple
sclerosis: Middle East and North Africa: regional recommendations for patient
selection and monitoring. BMC Neurol. 2014; 14: 27
3
8. AlTahan A, Alsharoqi I, Bohlega S, Dahdaleh M, Daif A, Deleu D, Esmat K,
Giampaolo D, Freedman M, GwilT M, Hosny H, Inshasi J, Aljumah M, Khalifa A,
Pakdaman H, Szolics M, Yamout B, Sahraian M, M Zakaria. Characteristics of
multiple sclerosis in the Middle East with special reference to the applicability of
international guidelines to the region. International Journal of Neuroscience 2014;
124:635-641
9. Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zaid N, Hamoulila K, Al
Halabi MS, Al Uqla Z, Al Hamadani H, Hamoodi H, Al Omar A, Dahdaleh M.
Multiple sclerosis in the Levant: a regional consensus statement. International
Journal of Neuroscience 2014 124:377-82.
10. Al Jumah M, Alroughani R, Alsharoqi I, Bohlega S, Dahdaleh M, Deleu D, Esmat
K, Khalifa A, Sahraian M, Szólics M, AlTahan A, Yamout B, Rieckmann P, A
Daif. Future of management of multiple sclerosis in the Middle East: a consensus
view from specialists in ten countries. Multiple Sclerosis International 2013;
2013:1-6
11. Yamout B; Al-Zaghal Z; El-Dahouk I; Farhat S; Sibai A; Hamdan A. Mean
Contact Quotient Using Electroglottography in Patients With Multiple Sclerosis.
Journal of Voice 2013; 27: 506-51
12. Yamout B; Alroughani R., Al-Jumah M., Khoury S., Abouzeid N., Dahdaleh M.,
Alsharoqi I., Inshasi J Hashem S., Zakaria M., El Kallab K., Alsaadi T., Tawfeek
T., Bohlega S. Consensus guidelines for the diagnosis and treatment of multiple
sclerosis. Current Medical Research and Opinion 2013; 29: 611-621
13. Yamout B; Issa Z; Herlopian A; El Bejjani M; Khalifa A; Ghadieh A; Habib R.
Predictors of Quality of Life among Multiple Sclerosis Patients: A Comprehensive
Analysis. Euro J Neurol 2013; 5: 756-764
14. Abboud H, Labreuche J, Arauz A, Bryer A, Lavados P, Massaro A, Collazos
M, Steg P, Yamout B, Vicaut
E, Amarenco
P. Demographics, socio-economic
characteristics, and risk factor prevalence in patients with non-cardioembolic
ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J
Stroke 2013; 100:4-13
15. Hamdan AL, Farhat S, Saadeh R, El-Dahouk I, Yamout B. Voice-related quality of
life in patients with multiple sclerosis. Autoimmune Diseases 2012; 2012:1438
16. Al-Tahan AM, Al-Jumah MA, Bohlega SM, Al-Shammari SN, Al-Sharoqi IA,
Hosny HM, Yamout B. The importance of quality-of-life assessment in the
management of patients with multiple sclerosis. Recommendations from the
Middle East MS Advisory Group. Neurosciences 2011; 16:109-113
4
17. Yamout B, Heropian A, Issa Z, Habib R, Fawwaz A, Salame J, Wadih A, Awdeh
H, Muallem N, Raad R, Al-Kutoubi A. Response to letter on extracranial venous
stenosis in relapsing-remitting multiple sclerosis patients. Mult Scler 2011; 17:
643-645.
18. Deleu D, Al Jumah M, Al-Tahan A, Bohlega S, Dahdaleh M, Inshasi J, Khalifa A,
Szolics M, Yamout B, Alsharoqi I. Will new injection devices for interferon beta-
1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert
opinion in the Middle East. Int J Neurosci 2011; 121:171-175.
19. Yamout B, Heropian A, Issa Z, Habib R, Fawwaz A, Salame J, Wadih A, Awdeh
H, Muallem N, Raad R, Al-Kutoubi A. Extracranial venous stenosis is an
unlikely cause of Multiple Sclerosis. Mult Scler 2010; 16: 1341.
20. Yamout B, Hourani R, Salti H., Barada W, El-Hajj T, Koutobi A, Herlopian A,
Bazz E, Mahfouz R, Khalil-Hamdan R, Kreidyeh N, El-Sabban M, Bazarbachi A.
Bone marrow mesenchymal stem cell transplantation in patients with multiple
sclerosis: a pilot study. Journal of Neuroimmunology 2010; 227: 185–189.
21. Masroujeh R, Otrock Z, Yamout B, Jabbour M, Bazarbachi A. Myasthenia gravis
developing in a patient with CNS lymphoma. International Journal of Hematology
2010; 120: 522-524.
22. Yamout B, Itani S, Hamzeh D, Arabi A, Yaghi S. Prognostic factors of Multiple
Sclerosis in Lebanon. The International Journal of Neuroscience, 2010; 120(3);
206-10.
23. Yamout B, Itani S, Hourany R, Mehio-Sibai A, Yaghi S. The effect of war stress
on Multiple Sclerosis exacerbations and radiological disease activity. Journal of the
Neurological Sciences, 2010; 288: 42-44.
24. Yamout B, Dahdaleh M, Al-Jumah MA, Al-Shammri S, Al. Sharoqi I, Al-Tahan
AR, Bohlega S, Deleu D, Inshasi J, Khalifa A, Szólics M. Adherence to disease
modifying drugs in patients with multiple sclerosis: A consensus statement from
the Middle East/Near East MS Advisory Group. The International Journal of
Neuroscience, 2010; 120(4):273-9.
25. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen
P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study
Group(Yamout B is listed as an investigator and member of the CLARITY Study
Group). A placebo-controlled trial of oral cladribine for relapsing multiple
sclerosis. N Engl J Med. 2010,362(5):416-26.
5
26. Yamout B., Fuleihan N, Hajj T, Sibai A, Sabra O, Rifai H, Hamdan AL. Vocal
symptoms and acoustic changes in relation to the expanded disability status scale,
duration and stage of disease in patients with multiple sclerosis. Eur Arch
Otorhinolaryngol, 2009; 266: 1759-1765.
27. Yamout B, Usta J, Itani S, Yaghi S. Celiac disease, Behçet, and Idiopathic
Thrombocytopenic Purpura in siblings of a patient with Multiple Sclerosis.
Multiple Sclerosis, 2009; 15: 1368-71.
28. Hourani R, El-Hajj T, Barada W, Hourani M, Yamout B*. MR Imaging Findings
in Autosomal Recessive Hereditary Spastic Paraplegia. American Journal of
Neuroradiology, May 2009; 30: 936-40.
29. Bohlega S, Al-Shammri S, Al. Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J,
Khalifa A, Pakdaman ., Szólics M, Yamout B*. Biosimilars: opinion of an expert
panel in the Middle East. Current Medical Research and Opinion, 2008; 24: 2897-
2903.
30. Yamout B, Barada W, Tohme RA, Mehio-Sibai A, Khalifeh R, El-Hajj T. Clinical
characteristics of Multiple Sclerosis in Lebanon. Journal of the Neurological
Sciences, 2008; 270: 88-93.
31. Sinno D, Darras B, Yamout B, Rebeiz J, Mikati M. A. Motor Variant of Chronic
Inflammatory Demyelinating Polyneuropathy in a child. Pediatric Neurology,
2008; 38: 426-429.
32. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati M. A. Predictors of bone
density in ambulatory patients on antiepileptic drugs. Bone, 2008; 43: 149-55.
33. Yamout B. Extreme Circumstances, extraordinary measures. Good Clinical
Practice Journal, 2008; 15: 33-35.
34. Hourani R, Barada W, El Hajj T, Hourani M, Yamout B*. Posterior column
atrophy in autosomal recessive hereditary spastic paraplegia: MRI findings.
European Journal of Radiology, 2008; 65: 37-41.
35. Yamout B, El-Hajj T, Barada W, Uthman I. Successful treatment of refractory
Neurosjogren with Rituximab. Lupus, 2007; 16: 521-523.
36. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, El-Hajj Fuleihan G.
Two randomized vitamin D trials in ambulatory patients on anticonvulsants:
Impact on bone (letter). Neurology, 2007; 68: 1958 - 1959.
6
37. Mikati M.A, Dib L, Yamout B, Sawaya R, Rahi AC and Fuleihan G. El-Hajj. Two
randomized vitamin D trials in ambulatory patients on anticonvulsants: Impact on
bone. Neurology, 2006; 67: 2005-2014.
38. Gus A. Baker, Ann Jacob, Joanne Gorry, Julie Doughty and Veronica Ellina, on
behalf of the SIGN Group (Yamout B.). Quality of life of people with epilepsy in
Iran, the gulf, and Near East. Epilepsia, 2005; 46 (1):132-140.
39. Kanj SS, Kanafani ZA, Khneisser I, Sawaya RA, Abdallah MS, Yamout B., Matar
GM. Human herpes virus 6 in patients with Bell’s palsy. J Appl Res 2003; 3:239-
241.
40. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, and the
Rizatriptan-ergotamine/Caffeine Preference Study Group (Yamout B.). Crossover
comparison of efficacy and preference for Rizatriptan 10 mg versus
Ergotamine/caffeine in migraine. Eur Neurol, 2003; 49:20-29.
41. Chehal A, Haidar JH, Jabbour R, Yamout B, Bazarbachi A. Obstructive sleep
apnea secondary to chronic lymphocytic leukemia. Ann Oncol, 2002; 13 (11):1833.
42. Farhat G, Yamout B, Mikati M.A, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect
of antiepileptic drugs on bone density in ambulatory patients. Neurology, 2002;
58:1348-1353.
43. Mansour A, Chamseddine A, Yamout B*, Solitary Metastasis to the Oculomotor
Nuclear complex. Annals of Ophthalmology, 2000; 32 (3):201-203.
44. Azar. S.T., Yamout B*. Prolactin secretion is increased in patients with multiple
sclerosis. Endocrine Research, 1999; 25: 207-14.
45. Nuwayhid I, Yamout B, Azar G. The effects of narghille smoking on pregnancy
outcome. The American Journal of Epidemiology, 1998; 148: 375-383.
46. Fayyad M, yamout B, Mroueh S. Alpha Interferon in the Treatment of Subacute
Sclerosing. Panencephalitis. Journal of Child Neurology, 1997; 12: 486-488.
47. Yamout B, Zaytoun G, Nuweihed I. The role of facial nerve conduction studies
and electromyography in predicting the outcome of Bell’s palsy. European Journal
of Neurology, 1997; 4: 1-4.
7
48. Deeb L, Yamout B, Shamseddine A, Shabb N, Uthman S. Meningeal
Carcinomatosis as the presenting manifestation of gastric adenocarcinoma.
American Journal of Gastroenterology, 1997; 92: 329-331.
49. Yamout B, Farhat W, Nuweihed I, Hushaymi I. Changes in migraine’s symptoms
from childhood to adolescence. European Neurology, 1996; 36:174-176.
50. Yamout B, Nassar N, Ghayyad E, Habbal A. Neurobrucellosis: Clinical
presentation, treatment and outcome in seven cases. Mediterranean Journal of
infectious and Parasitic Diseases, 1996; 11: 111-115.
51. Yamout B, Kyriakides T, Tamim W, Drousiotov A. Myalgia, neuromyopathy and
internalized capillaries. A steroid-responsisve syndrome. Acta Neurologica
Scandinavica, 1995; 91: 294-296.
52. Khalil A, Yamout B, Tabbal S, Salem Z, Mroueh A. Case report and review of
literature: leptomeningeal relapse in epithelial ovarian cancer. Gynecologic
Oncology, 1994; 54: 227-231.
53. Yamout B, Tayyim A, Farhat W. Meralgia paresthetica as a complication of
laparoscopic cholecystectomy. Clinical neurology and neurosurgery, 1994; 96:
143-144.
54. Francis GS, Bonni A, Shen Hechtman P, Yamout B, Carpenter S, Karpati G,
Chang PL. Metachromatic leukodystrophy: multiple nonfunctional and
pseudodeficiency alleles in a pedigree: problem with diagnosis and counseling.
Ann Neurol, 1993; 34: 212-218.
* Senior author
2. PRESENTATIONS AT MEETING
a. Oral Presentations:
1. Yamout B, Nassar N, Ghayyad E, Habbal A. Neurobrucellosis: Clinical
presentation, treatment and outcome in seven cases. Presented at the American
Academy of Neurology Meeting, San Francisco, 1996.
2. Fayyad M, Yamout B, Mroueh S. Alpha Interferon in the Treatment of Subacute
Sclerosing Panencephalitis. Presented at the International Workshop in Ankara,
1995.
8
3. Noureddine B, Yamout B. Visual field changes in multiple sclerosis. Presented at
the third International Meeting of the Pan-Arab Council of Ophtamology in
Marakesh, Morroco, 1995.
4. Yamout B, Carpenter S, Karpati G. A peculiar form of steroid resistant chronic
inflammatory myopathy. Neurology. Presented at the American Academy of
Neurology Meeting in Cincinati, 1988.
b. Posters:
1. Alroughani R, Aljumah MA, Aref H, Bohlega S, Al Sherooqi IA, Dahdaleh M, Feki
I, Al-Kawi MZ, Koussa S, Sahraian MA, Yamout B. Natalizumab Treatment for
Multiple Sclerosis: MENA (Middle East and North Africa) regional
recommendations for patient selection and monitoring. Presented at the 23rd
European Neurological Society Meeting, June 2013; Barcelona-Spain
2. Yamout B, Issa Z, Herlopian A, El-Bajjani M, Khalifa A, Habib RH. Predictors of
Quality of Life in Patients with Multiple Sclerosis: A Comprehensive Analysis.
Presentated at the American Academy of Neurology 63rd
Annual Meeting, April
2011; Honolulu-USA
3. Yamout B, Herlopian A, Issa Z, Habib R, Fawaz A, Salame J, Wadih A, Awdeh H,
Muallem N, Raad R, Al-Kutoubi A. Chronic cerebrospinal venous insufficiency is an
unlikely cause of multiple sclerosis. Presented at the 26th
Congress of the European
Committee for the Treatment and Research in Multiple Sclerosis, Gothenburg-
Sweden 2010. Nominated for best poster prize at the ECTRIMS 2010
4. Yamout B., Hourani R., Salti H., Barada W., El-Hajj T., Skaff G., Koutobi A., Bazz
E., Mahfouz R., Khalil-Hamdan R., Kreidyeh N., El-Sabban M., Bazarbachi A. Bone
marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a
pilot study. Presented at the 25th
congress of the European Committee for Treatment
and Research in Multiple Sclerosis, Düsseldorf, Germany 2009.
5. Clinical Characteristics of multiple sclerosis in Lebanon. Presented at the 23rd
congress of the European Committee for Treatment and Research in Multiple
Sclerosis, Prague, Czech Republic 2007 .
6. B. Yamout, G. Skaff, M. Khalife, W. Barada, R. Hourani, E. Bazz, R. Mahfouz, M.
Sabban, H. Khoury and A. Bazarbachi. Bone Marrow Mesenchymal Stem Cell
Transplantation in Patients with Multiple Sclerosis and Severe Disability: a Pilot
Study. Presented at the European Charcot Foundation Symposium, “Mending the
Brain”. Stem cells and repair in Multiple Sclerosis”, November 2006. Taormina
Sicily.
9
7. Yamout B, Azar S, Haidar S. Serum prolactin level during acute exacerbations of
multiple sclerosis. Presented at the Endocrine Society meeting in Anaheim _
California, June 1994.88
8. Karpati G, Carpenter S, Shoubridge E, Arnold D, Yamout B, Waddell R.
Mitochondrial myopathy in primary biliary cirrhosis: an antibody-mediated
cytopathy. Neurology, 38 (supl 1): 114, 1988.
9. Yamout B, Iannaccone S, Hug G. Infantile peripheral neuropathy associated with
carnitine deficiency. Neurology, 36 (supl 1): 81, 1986.
3. CURRENT RESEARCH
1. Rituximab therapy in multiple sclerosis patients failing on standard interferon
treatment. B. Yamout, A. Herlopian, M. Bajani
2. Human Herpes viridae infections and immune-related markers in the evolution of
multiple sclerosis. E. Rahhal, A. Abdelnoor, B. Yamout.
4. PAST INTERNATIONAL MULTICENTER TRIALS:
1. CLARITY trial: A Phase Ш, randomized, double-blind, three-arm, placebo-
controlled, multi-center study to evaluate the safety and efficacy of oral
Cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS)
2. CLARITY Extension trial: A Phase Шb, Double-Blind, Placebo-Controlled,
Multicenter, Parallel Group, Extension Trial to Evaluate the safety and
Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting
Multiple Sclerosis Who Have Completed Trial 25643 .
3. ATAMS trial: A four-arm randomized, double-blind, placebo-controlled,
multicenter Phase II study to evaluate the safety, tolerability and efficacy as
assessed by frequent MRI measures of three doses of Atacicept monotherapy
in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks
treatment course.
4. REFLEXION trial: Double-blind extension of the study 27025 (REFLEX) to
obtain long-term follow-up data in patients with clinically definite MS and
patients with a first demyelinating event at high risk of converting to MS,
treated with Rebif New Formulation
10
5. ATAMS Extension trial: An open label, multicenter phase II extension of
study 28063 (ATAMS) to obtain long term follow up data in subjects with
relapsing multiple sclerosis treated with Atacicept for up to 5 years .
6. ATONS trial: A two arm, randomized, double blind, placebo-controlled,
multicenter phase П study to evaluate safety and tolerability and to explore
the neuroprotective effect of Atacicept as assessed by Optical Coherence
Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically
Isolated Syndrome (CIS) over a 36 weeks treatment course.
7. REFLEX trial:A Phase III, randomized, double-blind, placebo-controlled,
multicenter clinical trial of Rebif® New Formulation (44 mcg tiw and 44
mcg ow) in subjects at high risk of converting to Multiple Sclerosis
8. ORACLE trial: A Phase III, randomized, double-blind, placebo-controlled,
multicenter clinical trial of oral cladribine in subjects with a first clinical event
at high risk of converting to MS (ORACLE MS).
5. INVITED PRESENTATIONS:
A. Local conferences:
April, 2015: Multiple sclerosis treatment guidelines
Lebanese Pharmacists Symposium
Beirut-Lebanon
November, 2014: Teriflunomide: A new approach to disease management in MS
The 6th
International Congress of the Lebanese Society of
Neurology
Beirut- Lebanon
March, 2014: Multiple sclerosis and pregnancy
Lebanese Society of Neurology Meeting
Dbayeh, Lebanon
October, 2012: Is it multiple sclerosis?
Lebanese Society of Family Medicine Annual conference
Beirut, Lebanon
11
July, 2011: New scope in multiple sclerosis
Novartis MS symposium
Saida, Lebanon
July, 2011: New perspectives in multiple sclerosis
Novartis MS symposium
Beirut, Lebanon
March, 2010: Stem cells, an evolving therapy in multiple sclerosis
Sixth Annual Congress of the Lebanese Order of Physicians
Tripoli, Lebanon
March, 2010: Pregnancy in multiple sclerosis
Sixth Annual Congress of the Lebanese Order of Physicians
Tripoli, Lebanon
February, 2010: Oral therapies in multiple sclerosis
Merck-Serono annual symposium on multiple sclerosis
Mount Lebanon, Lebanon
March, 2010: Management of pain in diabetic neuropathy
Lebanese ministry of health meeting
Beirut, Lebanon
October, 2009: Painful diabetic neuropathy
Lilly Symposium
Mount Lebanon, Lebanon
July, 2009: Management of painful diabetic polyneuropathy
Lilly Symposium
Beirut, Lebanon
March, 2009: Stem cell therapy in multiple sclerosis. A pilot trial.
The 11th
Medical Seminar on Actualities in Neurology.
Notre Dame Du Liban Hospital.
March, 2008: Preventive stroke therapy
Lebanese Society of Neurosurgery annual meeting
Beirut, Lebanon.
March, 2008: Update on medical therapy of stroke
AUB Department of Family Medicine town meeting.
Beirut, Lebanon.
12
.
May, 2007: Management of Insomnia.
Bekaa Sanofi-Aventis symposium on sleep.
Chtaura, Lebanon.
September, 2006: Medical therapy of stroke.
Bekaa Sanofi-Aventis symposium on stroke.
Chtaura, Lebanon.
May, 2006: Management of Insomnia
Beirut Sanofi-Aventis symposium on sleep.
Beirut, Lebanon.
December, 2005: Role of neutralizing antibodies in interferon-treated MS
patients.
Serono symposium on early treatment in multiple
Sclerosis.
Beirut- Lebanon.
.
B. Regional conferences:
April, 2015: Safety and efficacy of Natalizumab
Iraqi Expert Meeting
Amman-Jordan
April, 2015: Natalizumab real world evidence: The Lebanese Cohort
Iraqi Expert Meeting
Amman-Jordan
April, 2015: MENACTRIMS guidelines for treatment of multiple clerosis
Iraqi Expert Meeting
Amman-Jordan
13
February, 2015: Oral DMTs: Spotlight on Teriflunomide
Treatment Paradigm in Evolving MS Landscape: Genpharm
Symposium
Dubai-UAE
February, 2015: Consensus recommendations for the treatment of MS
The 9th
Annual Egyptian Symposium on Epilepsy and Multiple
Sclerosis
Istanbul-Turkey
November, 2014: Current Approach to MS treatment
The 9th
GCC Neurology Conference
Muscat-Oman
November, 2014: Alemtuzumab experience in the Middle East
Genzyme Advisory Board Meeting
Muscat-Oman
October, 2014: New approach in MS therapy
The 11th
International Congress on MS in Iran
Genzyme Symposium
Tehran-Iran
October, 2014: Consensus recommendations for diagnosis and treatment of MS;
The MENACTRIMS Guidelines
First MENACTRIMS Congress
Dubai-UAE
October, 2014: Patient centric outcomes
Merck-Serono symposium
First MENACTRIMS C
Dubai-UAE
September, 2014: Time for change: Advancing our understanding of MS
Le 20eme Congres National De Neurologie
Novartis Symposium
Hammamat-Tunis
September, 2014: MENACTRIMS consensus guidelines for treatment of MS
Biologix Advisory Board Meeting
Dead Sea, Jordan
September, 2014: Personalizing treatment choices in MS
14
Jordan Neurological Society Meeting
Biologix Symposium
Dead Sea, Jordan
June, 2014: A new approach for treatment of relapsing MS
21th Congress of Neurology and Electrophysiology of Iran.
Tehran, Iran
June, 2014: Real world evidence: Effect of switching to fingolimod on
effectiveness, patient related outcomes, and adherence.
STEP Dubai Medical Summit
Dubai, UAE
April, 2014: The case for injectable vs oral therapies in MS
UAE Neurology Society Symposium: Changing MS landscape. A
debate for best patient’s outcome
Dubai, UAE
April, 2014: Diagnosing MS: The Middle East Guidelines
UAE Neurology Society Symposium: Changing MS landscape. A
debate for best patient’s outcome
Dubai, UAE
February, 2014: The Levant Experience with Fingolimod
UAE MS Forum
Dubai- UAE
February, 2014: The case for teriflunomide as first line therapy in MS
UAE MS Forum
Dubai- UAE
February, 2014: Multiple Sclerosis and Stress
The First Challenges in Clinical Neurology Congress
Kerman-Iran
November, 2013: Transition to new outcome measures in MS
The 8th
Middle East Merck Serono Multiple Sclerosis Advisory
Board Meeting
Istanbul-Turkey
November, 2013: Multiple Sclerosis and Stress
The 5th International Congress of the Lebanese Society of
Neurology
Beirut- Lebanon
November, 2013: Aubagio (Teriflunomide): A new approach to disease
15
Management
Genpharm-Genzyme Symposium
The 5th International Congress of the Lebanese Society of
Neurology
Beirut- Lebanon
May, 2013: Future Therapies in Multiple Sclerosis
The First Multiple Sclerosis Update Middle East Forum 2013-UAE
Abu Dhabi- UAE
May, 2013: Current Treatment of Multiple Sclerosis
The First Multiple Sclerosis Update Middle East Forum 2013-UAE
Abu Dhabi- UAE
April, 2013: Fingolimod Update from the American Academy of Neurology 2013
Transforming MS Treatment -Novartis Symposium
The First Kuwait North American Neurology Conference
Kuwait City- Kuwait
April, 2013: Health Economics in Multiple Sclerosis
The Iraqi National Committee Symposium
Sponsored by Novartis
Beirut- Lebanon
April, 2013: Two Years of Oral Therapy Experience in the Middle East
The Iraqi National Committee Symposium
Sponsored by Novartis
Beirut- Lebanon
April, 2013: Future Oral Therapies in Multiple Sclerosis
The Iraqi National Committee Symposium
Sponsored by Novartis
Beirut- Lebanon
April, 2013: Guidelines for management of multiple sclerosis
The Iraqi National Committee Symposium
Sponsored by Novartis
Beirut- Lebanon
February, 2013: Diagnosis and management of multiple sclerosis:
Practice Guidelines
The 13th
Congress of the Pan Arab Union of Neurological
Societies
Sharm El Sheikh- Egypt
February, 2013: Treatment of multiple sclerosis
16
Iraqi physicians training program at AUBMC
Beirut- Lebanon
January, 2013: Updated guidelines for multiple sclerosis therapy
The 7th
Educational Egyptian Epilepsy Association Symposium and
Multiple Sclerosis Update
Beirut- Lebanon
January, 2013: New oral therapies in multiple sclerosis
The 7th
Educational Egyptian Epilepsy Association Symposium and
Multiple Sclerosis Update
Beirut- Lebanon
December, 2012: Epidemiology of multiple sclerosis in Lebanon
MS in the 21st Century: The Seventh Intercontinental Multiple
Sclerosis Advisory Board Meeting
Dubai-UAE
November, 2012: Cerebrospinal Venous Insufficiency and MS
The 5th
International Congress of the Jordanian Society of
Neurology
Amman-Jordan
September, 2012: Stem Cells in MS
The Salim El-Hoss Bioethics and Professionalism Program
3rd
regional conference.
Stem Cell Research: Current Controversies
Beirut-Lebanon
June, 2012: Unmet needs in MS treatment
United Arab Emirates MS Advisory Board Meeting
Dubai-UAE
June, 2012: New Oral Therapies in MS
United Arab Emirates MS Advisory Board Meeting
Dubai-UAE
June, 2012: New Oral Therapies in MS
Egyptian MS Society Annual Meeting
Alexandria-Egypt
June, 2012: Multiple sclerosis in Lebanon
Multiple Sclerosis and Molecular Aspects in the Arab World
Arab Gulf University
Manama-Bahrain
17
June, 2012: Fingolimod: Clinical Experience in the Middle East as first line therapy
Middle East Perspectives in Neuroscience
Kuala Lumpur-Malaysia
May, 2012: Symptoms and diagnosis of MS
Kuwaiti Multiple Sclerosis Society Annual Meeting
Kuwait City-Kuwait
May, 2012 : Unmet needs in MS therapy
Novartis Regional MS Symposium
Beirut-Lebanon
May, 2012 : Fingolimod in MS therapy
Novartis Regional MS Symposium
Beirut-Lebanon
May, 2012 : New oral therapies in multiple sclerosis
The Second AUBMC Multiple Sclerosis Center Symposium
Beirut-Lebanon
May, 2012 : American University of Beirut Medical Center multiple sclerosis
practice guidelines
The Second AUBMC Multiple Sclerosis Center Symposium
Beirut-Lebanon
March, 2012 : Unmet needs in current multiple sclerosis therapy
Middle East Advisory Board meeting
Dubai-UAE
September, 2011 : Unmet needs in multiple sclerosis
Novartis Symposium
Broumana-Lebanon
September, 2011 : Fingolimod indications in clinical practice
Novartis Symposium
Broumana-Lebanon
July, 2011 : Innovative approach in treatment of Multiple Sclerosis
Iraqi neurology society meeting
Novartis symposium
Erbil-Iraq
March, 2011: Early Treatment and cognitive functioning in MS: Current evidence
Iraqi neurology society meeting
Bayer symposium
18
Erbil-Iraq
March, 2011: Treating MS today: Balancing the therapeutic risk-benefit ratio
Iraqi neurology society meeting
Bayer symposium
Erbil-Iraq
January, 2011: The theory of CCSVI in Multiple Sclerosis.
The Annual Multiple Sclerosis and Epilepsy Update Symposium
Cairo- Egypt
January, 2011: Stem cell in Multiple sclerosis.
The Annual Multiple Sclerosis and Epilepsy Update Symposium
Cairo- Egypt
January, 2011: Chronic cerebrospinal venous insufficiency in multiple sclerosis
King Faysal hospital - Neurology Grand Round
Riyadh- Saudi Arabia
November, 2010: Antiplatelets in Preventive Stroke Therapy
Sanofi-Aventis symposium on stroke and epilepsy
Istanbul-Turkey
September, 2010: Extracranial venous stenosis is an unlikely cause of multiple
Sclerosis
11th
Neuromediterranean Congress
Beirut-Lebanon
May, 2010: Oral Therapies in Multiple Sclerosis
12th
Congress of the Pan Arab Union of Neurological Societies
Damascus-Syria
April, 2010: Stem cell therapy in multiple sclerosis
43d Middle East Medical Assembly annual meeting
Beirut, Lebanon
April, 2010 : Multiple sclerosis diagnosis
Syrian society of neurology annual meeting
Damascus, Syria
February, 2010 : Treatment adherence to in multiple sclerosis
The Middle East Advisory Board on Multiple Sclerosis annual
meeting
Mount Lebanon, Lebanon
19
October, 2009 : Oral therapies in multiple sclerosis
The Sixth Iranian International Congress on Multiple Sclerosis
Tabriz, Iran
February, 2009: Secondary stroke prevention: an update
Jordanian neurology society symposium on stroke and epilepsy
Dead Sea- Jordan.
November, 2008: Update on Multiple Sclerosis
International Congress on Multiple Sclerosis of Iran.
Tehran- Iran.
December, 2007: Update on medical therapy of stoke
Jordanian neurology society symposium on stroke and
epilepsy
Dead Sea- Jordan.
November, 2005: Early vs. delayed treatment in multiple sclerosis
Pan-Gulf neurology meeting.
Manama, Bahrain.
.
February, 2005: Preventive stroke therapy
The Iraqi neurology society annual conference.
Cairo- Egypt.
.
January, 2005: Multiple sclerosis and women.
Symposium on neurological diseases in women.
Kuwait city- Kuwait.
May, 2003: Early treatment of multiple sclerosis
Tenth international Iranian congress on neurology
Tehran- Iran.
.
May, 2002: a. Etiology and pathogenesis of multiple sclerosis.
b. Progression of disability in multiple sclerosis: mechanism,
clinical and MRI parameters.
Kuwaiti MS forum.
20
Kuwait city- Kuwait
April, 2000: Early Axonal Loss in Multiple Sclerosis: A New Disease Concept
The 8th
. Congress of the Pan Arab Union of Neurological Societies
Beirut-Lebanon:
.
C. International conferences:
March, 2015: Natalizumab efficacy and safety: Growing evidence from real life
Expect more in MS: Genzyme Symposium
Rome-Italy
December, 2014: Personalizing treatment choices in MS
Biologix Symposium
Paris-France
May, 2014: Patients related outcomes in MS
Serono Symposia International 2014 Annual Conference
Dubai-UAE
April, 2014: New directions and emerging therapies in MS
Second Multiple Sclerosis and Parkinson's Disease Workshop
Malaysian Society of Neurosciences
Kuala Lumpur, Malaysia
April, 2014: Brain volume loss in MS and its correlation to clinical outcomes
Second Multiple Sclerosis and Parkinson's Disease Workshop
Malaysian Society of Neurosciences
Kuala Lumpur, Malaysia
November, 2013: Can Stress Exacerbate MS?
3d International Congress of Neurology and epidemiology
Abu Dhabi-UAE
November, 2013: Practice Guidelines for the Management of Multiple Sclerosis
Merck-Serono Symposium
3d International Congress of Neurology and epidemiology
Abu Dhabi-UAE
November, 2013: Multiple Sclerosis: The Importance of Treatment Adherence
Merck-Serono Symposium
3d International Congress of Neurology and epidemiology
Abu Dhabi-UAE
June, 2012: Summary of fingolimod efficacy data
21
MS STEP Meeting
Kuala Lumpur-Malaysia
June, 2012: Fingolimod safety data and risk management
MS STEP Meeting
Kuala Lumpur-Malaysia
November, 2011: Multiple Sclerosis and Chronic Cerebrospinal Venous
Insufficiency.
XXth World Congress of Neurology
Marrakesh-Morocco
March, 2011: Epidemiology and clinical characteristics of MS in the Middle
East.
Eighth Regional MS Forum
Seville-Spain
May, 2010: Bone Marrow Mesenchymal Stem Cell Transplantation in Patients
With Multiple Sclerosis: A Pilot Study
Annual World Congress of Immunodiseases and Therapy 2010
(WCIT- 2010)
Beijing-China
May, 2010: Stem cells in multiple sclerosis
5th EEMCPDM meeting (Eastern European and Mediterranean
Cerebral Palsy and Developmental Medicine)
Beirut-Lebanon
October, 2007: Managing Clinical Trials Under War Conditions. The 2006
Lebanese-Israeli war experience.
2nd
Annual European Clinical Research Conference.
Madrid, Spain.
February, 2004: Neutralizing antibodies in INFB- treated multiple sclerosis
patients.
Serono regional meeting on treatment of multiple sclerosis.
Gstaad- Switzerland
October, 2002: Etiology and pathogenesis of multiple sclerosis: new concepts.
Serono regional meeting on multiple sclerosis.
Nairobi- Kenya.
22
5. EDITORIAL BOARDS:
Member, editorial board of Multiple Sclerosis and Related Disorders
Member, editorial board of Journal of Multiple Sclerosis
Member, editorial board of Annals of Autoimmunity and Research
Chief Editor, MS Today: newsletter on MS.
Member, review board of: Journal of Pediatric Neurology.
C. SERVICE:
1. PROFESSIONAL PRACTICE AND COMMUNITY:
President, MENACTRIMS
Head, Multiple Sclerosis Clinic and Research Center (2008-Present).
President of the National Multiple Sclerosis Society of Lebanon.
2. SERVICE TO THE PROFESSION:
Member of the Regional Advisory Board for Multiple Sclerosis in the
Middle East (sponsored my Merck-Serono Pharmaceuticals): 2007-
Present.
Member of the Intercontinental Advisory Board for Multiple Sclerosis
(sponsored by Merck-Serono Pharmaceuticals): 2009-Present.
Member of the Multiple Sclerosis Board for Asia-Pacific, Middle East &
Africa (sponsored by Novartis): 2010-Present.
Member of the King Faisal Foundation selection committee for the King
Faisal International Prize in Medicine: 2010-2011
Member of the Parliamentary national health committee: 2000-2005.
23
top related